Grace Therapeutics (NASDAQ:GRCE) Stock Rating Upgraded by Wall Street Zen

Grace Therapeutics (NASDAQ:GRCE) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a note issued to investors on Friday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Grace Therapeutics in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Grace Therapeutics presently has an average rating of “Hold” and an average price target of $12.00.

Grace Therapeutics Trading Up 0.5%

GRCE opened at $3.82 on Friday. The stock’s 50-day moving average price is $3.41 and its 200 day moving average price is $3.22. Grace Therapeutics has a 12-month low of $1.75 and a 12-month high of $3.99. The firm has a market cap of $59.10 million, a price-to-earnings ratio of -6.16 and a beta of 0.55.

Grace Therapeutics (NASDAQ:GRCE) last released its earnings results on Thursday, November 13th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.03). On average, research analysts forecast that Grace Therapeutics will post -1.06 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Palumbo Wealth Management LLC purchased a new stake in shares of Grace Therapeutics in the 2nd quarter valued at approximately $144,000. Millington Financial Advisors LLC acquired a new position in shares of Grace Therapeutics during the second quarter worth $59,000. SeaCrest Wealth Management LLC acquired a new position in shares of Grace Therapeutics during the third quarter worth $42,000. ADAR1 Capital Management LLC increased its holdings in Grace Therapeutics by 98.4% in the third quarter. ADAR1 Capital Management LLC now owns 350,450 shares of the company’s stock valued at $1,043,000 after buying an additional 173,823 shares during the last quarter. Finally, Stratos Wealth Partners LTD. acquired a new stake in Grace Therapeutics in the fourth quarter valued at $39,000. Hedge funds and other institutional investors own 6.08% of the company’s stock.

Grace Therapeutics Company Profile

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.